Clinical Trial Update: Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating adalimumab dose reduction to achieve low serum concentrations while maintaining disease control in rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Reade Rheumatology Research Institute | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED